News >

Atezolizumab Plus Cobimetinib/Vemurafenib Meets PFS Endpoint in Frontline BRAF V600+ Advanced Melanoma

Gina Columbus @ginacolumbusonc
Published: Friday, Dec 13, 2019

Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development of Genentech (Roche)

Levi Garraway, MD, PhD

The triplet regimen of atezolizumab (Tecentriq), cobimetinib (Cotellic), and vemurafenib (Zelboraf) was found to improve progression-free survival (PFS) compared with cobimetinib/vemurafenib plus placebo in patients with previously untreated BRAF V600 mutation–positive advanced melanoma, meeting the primary endpoint of the phase III IMspire150 study (NCT02908672).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication